That doesn't really make sense. Target specifically, and it only takes a minor mutation to escape.
A less-specific vaccine would create immunity against multiple targets, and would logically require more simultaneous mutations to create an escape variant.
Unless your goal is to sell a new vaccine every year (chase your own escape variants, immunity-as-a-service), then MRNA isn't obviously a win.
A less-specific vaccine would create immunity against multiple targets, and would logically require more simultaneous mutations to create an escape variant.
Unless your goal is to sell a new vaccine every year (chase your own escape variants, immunity-as-a-service), then MRNA isn't obviously a win.